EUVIMEDEUVIMED entdecken
Open Access

Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus

Jorge Romo-Tena iD, Shouvonik Sengupta, Carmelo Carmona-Rivera, Shuichiro Nakabo, Gyeong Min Kim, William G Ambler, Eduardo Patino-Martinez, Luz P Blanco, Victoria Hoffmann, Shairaz Shah, Jennifer Zeng, Ashley Mahne und 3 weitere

The Journal of Immunology · 2026

DOI: 10.1093/jimmun/vkag112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Jorge Romo-Tena und 14 weiteren Autor:innen. Beteiligte Einrichtung: Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Uni…. Hauptthemen laut MEDLINE: Antigens, CD19, Lupus Erythematosus, Systemic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Kyverna Therapeutics, Inc., Intramural Research Program at NIAMS/National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus. An unresolved question is how immunosuppressive preconditioning regimens influence CAR-T cell engraftment and therapeutic efficacy. In murine models, whole-body irradiation is required for optimal CAR-T cell engraftment. However, irradiation alone can ameliorate lupus disease, confounding attribution of CAR-T–specific effects. To delineate the contribution of CAR-T cells beyond irradiation, we investigated how conditioning intensity shapes immunologic and physiological outcomes in lupus-prone New Zealand Black/New Zealand White (NZB/W) F1 mice. We generated murine anti-CD19 CAR-T cells incorporating a CD28 costimulatory domain and compared their efficacy following low-, intermediate- and high-dose irradiation. High-dose irradiation induced disease improvement that limited mechanistic discrimination between irradiation- and CAR-T–mediated effects, whereas low-dose irradiation failed to support durable CAR-T cell engraftment. In contrast, an intermediate-dose irradiation regimen in 22-week-old mice achieved consistent CAR-T cell engraftment in lymphoid organs while minimizing irradiation-driven disease modulation. Under these conditions, CAR-T cell treatment induced significant depletion of B cells in blood and spleen, including naïve B cells, marginal zone B cells, and plasma cells, accompanied by reduced anti–double-stranded DNA antibody levels and prevention of renal disease progression. Collectively, these findings demonstrate that intermediate-intensity conditioning enables mechanistic separation of CAR-T–mediated immune remodeling from irradiation effects in murine lupus and provide a preclinical framework that aligns with the pressing need for reduced-intensity lymphodepletion strategies in human CAR-T therapy for autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Lupus Erythematosus, SystemicImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesTransplantation ConditioningAnimalsMiceFemaleMice, Inbred NZBDisease Models, AnimalWhole-Body IrradiationAntibodies, AntinuclearB-Lymphocytes

Stichwörter der Autor:innen

B cellsCAR-T cell therapieslupus nephritismurine lupussystemic lupus erythematosus

Substanzen

Antigens, CD19Receptors, Chimeric AntigenAntibodies, Antinuclear

Autor:innen und Institutionen

  • Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States.
  • Research & Development, Kyverna Therapeutics, Inc., Emeryville, CA, United States.
  • Diagnostic and Research Services Branch, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, United States.

ORCID-Profile: Jorge Romo-Tena

Förderung

  • Intramural NIH HHS
  • Kyverna Therapeutics, Inc.
  • Intramural Research Program at NIAMS/National Institutes of Health (NIH)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Zitieren

APA

Romo-Tena, J., Sengupta, S., Carmona-Rivera, C., Nakabo, S., Kim, G. M., Ambler, W. G., Patino-Martinez, E., Blanco, L. P., Hoffmann, V., Shah, S., Zeng, J., Mahne, A., Cheng, J. K., Van Blarcom, T., & Kaplan, M. J. (2026). Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag112

Vancouver

Romo-Tena J, Sengupta S, Carmona-Rivera C, Nakabo S, Kim GM, Ambler WG, et al. Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag112

BibTeX
@article{RomoTena2026,
  author = {Romo-Tena, Jorge and Sengupta, Shouvonik and Carmona-Rivera, Carmelo and Nakabo, Shuichiro and Kim, Gyeong Min and Ambler, William G and Patino-Martinez, Eduardo and Blanco, Luz P and Hoffmann, Victoria and Shah, Shairaz and Zeng, Jennifer and Mahne, Ashley and Cheng, Joseph K and Van Blarcom, Tom and Kaplan, Mariana J},
  title = {Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus},
  journal = {The Journal of Immunology},
  year = {2026},
  doi = {10.1093/jimmun/vkag112}
}
Kostenlos starten →